循环肿瘤DNA在转移性乳腺癌中的有效性及潜在用途。
Circulating tumor DNA validity and potential uses in metastatic breast cancer.
作者信息
Amato Ottavia, Giannopoulou Nefeli, Ignatiadis Michail
机构信息
Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy.
Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
出版信息
NPJ Breast Cancer. 2024 Mar 12;10(1):21. doi: 10.1038/s41523-024-00626-6.
Abstract
Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s, recent advances led to its introduction in the clinics. At present, the European Society Of Medical Oncology (ESMO) recommendations endorse ctDNA testing in routine clinical practice for tumor genotyping to direct molecularly targeted therapies in patients with metastatic cancer. In studies on metastatic breast cancer, ctDNA has been utilized for treatment tailoring, tracking mechanisms of drug resistance, and for predicting disease response before imaging. We review the available evidence regarding ctDNA applications in metastatic breast cancer.
摘要
在20世纪90年代循环肿瘤DNA（ctDNA）首次被鉴定出来之后，最近的进展使其得以应用于临床。目前，欧洲医学肿瘤学会（ESMO）的建议支持在常规临床实践中进行ctDNA检测，以用于肿瘤基因分型，从而指导转移性癌症患者的分子靶向治疗。在转移性乳腺癌的研究中，ctDNA已被用于治疗方案的定制、追踪耐药机制以及在影像学检查之前预测疾病反应。我们综述了关于ctDNA在转移性乳腺癌中应用的现有证据。
相似文献
1
Circulating tumor DNA validity and potential uses in metastatic breast cancer.
NPJ Breast Cancer. 2024 Mar 12;10(1):21. doi: 10.1038/s41523-024-00626-6.
2
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Ann Oncol. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. Epub 2022 Jul 6.
3
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5.
4
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
5
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.
6
Circulating tumor DNA: current challenges for clinical utility.
J Clin Invest. 2022 Jun 15;132(12). doi: 10.1172/JCI154941.
7
Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA.
Urol Oncol. 2018 Aug;36(8):380-384. doi: 10.1016/j.urolonc.2017.11.017. Epub 2017 Dec 14.
8
Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Drug Discov Today. 2023 Apr;28(4):103540. doi: 10.1016/j.drudis.2023.103540. Epub 2023 Feb 21.
9
The potential of ctDNA analysis in breast cancer.
Crit Rev Clin Lab Sci. 2020 Jan;57(1):54-72. doi: 10.1080/10408363.2019.1670615. Epub 2019 Nov 1.
10
Circulating Tumor DNA in Breast Cancer: Current and Future Applications.
Clin Breast Cancer. 2023 Oct;23(7):687-692. doi: 10.1016/j.clbc.2023.06.008. Epub 2023 Jun 20.
引用本文的文献
1
The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer.
Cancers (Basel). 2025 Sep 8;17(17):2938. doi: 10.3390/cancers17172938.
2
Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives.
Explor Target Antitumor Ther. 2025 Aug 8;6:1002333. doi: 10.37349/etat.2025.1002333. eCollection 2025.
3
Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer.
Mol Diagn Ther. 2025 Sep;29(5):603-615. doi: 10.1007/s40291-025-00800-x. Epub 2025 Aug 7.
4
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
NPJ Breast Cancer. 2025 Aug 7;11(1):86. doi: 10.1038/s41523-025-00805-z.
5
Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer.
Curr Oncol. 2025 Jun 26;32(7):373. doi: 10.3390/curroncol32070373.
6
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapy.
NPJ Breast Cancer. 2025 Jul 19;11(1):74. doi: 10.1038/s41523-025-00783-2.
7
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives.
Ther Adv Med Oncol. 2025 Jul 10;17:17588359251353623. doi: 10.1177/17588359251353623. eCollection 2025.
8
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828.
9
Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.
Int J Mol Sci. 2025 May 23;26(11):5013. doi: 10.3390/ijms26115013.
10
Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring.
Indian J Med Res. 2025 Mar;161(3):267-277. doi: 10.25259/IJMR_1291_2024.
本文引用的文献
1
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Ann Oncol. 2024 Mar;35(3):267-275. doi: 10.1016/j.annonc.2023.12.007. Epub 2023 Dec 23.
2
ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies.
Ann Oncol. 2023 Nov;34(11):955-959. doi: 10.1016/j.annonc.2023.09.3111.
3
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Cancer Discov. 2024 Feb 8;14(2):274-289. doi: 10.1158/2159-8290.CD-22-1387.
4
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573.
5
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
Ann Oncol. 2023 Nov;34(11):1003-1014. doi: 10.1016/j.annonc.2023.08.011. Epub 2023 Sep 5.
6
Therapeutic resistance to anti-oestrogen therapy in breast cancer.
Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27.
7
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Clin Cancer Res. 2023 Oct 13;29(20):4166-4177. doi: 10.1158/1078-0432.CCR-23-0956.
8
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19.
9
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.
10
Design of SERENA-6, a phase III switching trial of camizestrant in -mutant breast cancer during first-line treatment.
Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
Zotero 插件